EPRX
Eupraxia Pharmaceuticals Inc.
Biotechnology
Market Cap$249M
5Y Perf.+171.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
EPRX vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.62B
5Y Perf.-64.1%
EPRX vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EPRX | PRGO |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $249M | $1.62B |
| Revenue (TTM) | $0.00 | $4.18B |
| Net Income (TTM) | $-47M | $-1.82B |
| Gross Margin | — | 34.2% |
| Operating Margin | — | -4.1% |
| Forward P/E | — | 5.5x |
| Total Debt | $154K | $3.97B |
| Cash & Equiv. | $80M | $532M |
EPRX vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EPRX
PRGO
| Stock | Apr 24 | May 26 | Return |
|---|---|---|---|
| Eupraxia Pharmaceut… (EPRX) | 100 | 271.9 | +171.9% |
| Perrigo Company plc (PRGO) | 100 | 35.9 | -64.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EPRX vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRGO leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Eupraxia Pharmaceuticals Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
EPRX
Eupraxia Pharmaceuticals Inc.
The Growth Play
EPRX is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth -38.2%
- 152.5% 10Y total return vs PRGO's -77.7%
- Lower volatility, beta 1.36, Low D/E 0.2%, current ratio 15.12x
Best for: growth exposure and long-term compounding
PRGO
Perrigo Company plc
The Income Pick
PRGO carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 10 yrs, beta 1.21, yield 9.8%
- Beta 1.21, yield 9.8%, current ratio 2.76x
- -2.8% revenue growth vs EPRX's -42.8%
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRGO | -2.8% revenue growth vs EPRX's -42.8% |
| Quality / Margins | EPRX | 1.7% margin vs PRGO's -43.5% |
| Stability / Safety | PRGO | Beta 1.21 vs EPRX's 1.36 |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | EPRX | +96.1% vs PRGO's -52.0% |
| Efficiency (ROA) | PRGO | -19.8% ROA vs EPRX's -70.9%, ROIC 3.7% vs -794.8% |
EPRX vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
EPRX vs PRGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEPRXLAGGINGPRGO
PRGOPerrigo Company plc
1leads
EPRXEupraxia Pharmaceutic…
2leads
6 Total Categories
CATEGORYLEADERvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
EPRX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRGO4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
EPRX6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
EPRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PRGO and EPRX operate at a comparable scale, with $4.2B and $0 in trailing revenue.
| Metric | EPRXEupraxia Pharmace… | PRGOPerrigo Company p… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $4.2B |
| EBITDAEarnings before interest/tax | -$47M | $58M |
| Net IncomeAfter-tax profit | -$47M | -$1.8B |
| Free Cash FlowCash after capex | -$29M | $108M |
| Gross MarginGross profit ÷ Revenue | — | +34.2% |
| Operating MarginEBIT ÷ Revenue | — | -4.1% |
| Net MarginNet income ÷ Revenue | — | -43.5% |
| FCF MarginFCF ÷ Revenue | — | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -61.9% | -56.4% |
EPRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — EPRX and PRGO each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | EPRXEupraxia Pharmace… | PRGOPerrigo Company p… |
|---|---|---|
| Market CapShares × price | $249M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $169M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -7.10x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.53x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.43x |
| Price / SalesMarket cap ÷ Revenue | — | 0.38x |
| Price / BookPrice ÷ Book value/share | 3.71x | 0.55x |
| Price / FCFMarket cap ÷ FCF | — | 11.17x |
Evenly matched — EPRX and PRGO each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRGO leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
PRGO delivers a -50.7% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-75 for EPRX. EPRX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x.
| Metric | EPRXEupraxia Pharmace… | PRGOPerrigo Company p… |
|---|---|---|
| ROE (TTM)Return on equity | -75.4% | -50.7% |
| ROA (TTM)Return on assets | -70.9% | -19.8% |
| ROICReturn on invested capital | -794.8% | +3.7% |
| ROCEReturn on capital employed | -69.7% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 1.35x |
| Net DebtTotal debt minus cash | -$80M | $3.4B |
| Cash & Equiv.Liquid assets | $80M | $532M |
| Total DebtShort + long-term debt | $153,953 | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | — | -7.20x |
PRGO leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
EPRX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in EPRX five years ago would be worth $25,254 today (with dividends reinvested), compared to $3,969 for PRGO. Over the past 12 months, EPRX leads with a +96.1% total return vs PRGO's -52.0%. The 3-year compound annual growth rate (CAGR) favors EPRX at 36.2% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | EPRXEupraxia Pharmace… | PRGOPerrigo Company p… |
|---|---|---|
| YTD ReturnYear-to-date | -1.6% | -13.6% |
| 1-Year ReturnPast 12 months | +96.1% | -52.0% |
| 3-Year ReturnCumulative with dividends | +152.5% | -58.1% |
| 5-Year ReturnCumulative with dividends | +152.5% | -60.3% |
| 10-Year ReturnCumulative with dividends | +152.5% | -77.7% |
| CAGR (3Y)Annualised 3-year return | +36.2% | -25.2% |
EPRX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — EPRX and PRGO each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRGO is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than EPRX's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EPRX currently trades 79.9% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EPRXEupraxia Pharmace… | PRGOPerrigo Company p… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.36x | 1.21x |
| 52-Week HighHighest price in past year | $9.32 | $28.44 |
| 52-Week LowLowest price in past year | $3.67 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +79.9% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 52.5 | 53.1 |
| Avg Volume (50D)Average daily shares traded | 194K | 3.3M |
Evenly matched — EPRX and PRGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates EPRX as "Buy" and PRGO as "Hold". Consensus price targets imply 209.1% upside for PRGO (target: $36) vs 155.0% for EPRX (target: $19). PRGO is the only dividend payer here at 9.82% yield — a key consideration for income-focused portfolios.
| Metric | EPRXEupraxia Pharmace… | PRGOPerrigo Company p… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $19.00 | $36.20 |
| # AnalystsCovering analysts | 2 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
EPRX leads in 2 of 6 categories (Income & Cash Flow, Total Returns). PRGO leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallEupraxia Pharmaceuticals In… (EPRX)Leads 2 of 6 categories
Loading custom metrics...
EPRX vs PRGO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is EPRX or PRGO a better buy right now?
Analysts rate Eupraxia Pharmaceuticals Inc.
(EPRX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EPRX or PRGO?
Over the past 5 years, Eupraxia Pharmaceuticals Inc.
(EPRX) delivered a total return of +152. 5%, compared to -60. 3% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: EPRX returned +152. 5% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EPRX or PRGO?
By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.
21β versus Eupraxia Pharmaceuticals Inc. 's 1. 36β — meaning EPRX is approximately 12% more volatile than PRGO relative to the S&P 500. On balance sheet safety, Eupraxia Pharmaceuticals Inc. (EPRX) carries a lower debt/equity ratio of 0% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
04Which is growing faster — EPRX or PRGO?
On earnings-per-share growth, the picture is similar: Eupraxia Pharmaceuticals Inc.
grew EPS -38. 2% year-over-year, compared to -723. 2% for Perrigo Company plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EPRX or PRGO?
Eupraxia Pharmaceuticals Inc.
(EPRX) is the more profitable company, earning 0. 0% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus 0. 0% for EPRX. At the gross margin level — before operating expenses — PRGO leads at 35. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is EPRX or PRGO more undervalued right now?
Analyst consensus price targets imply the most upside for PRGO: 209.
1% to $36. 20.
07Which pays a better dividend — EPRX or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. EPRX does not pay a meaningful dividend and should not be held primarily for income.
08Is EPRX or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
21), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, EPRX: +152. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between EPRX and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EPRX is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while EPRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.